
GSK Marks Second Lung Cancer Drug Approval This Year
Summary
The Food and Drug Administration has granted accelerated approval to a new lung cancer treatment developed by GSK. This regulatory decision represents the second time this year that the European pharmaceutical company has secured approval for a lung cancer therapy.
On Tuesday, the Food and Drug Administration granted accelerated approval to GSK Plc.’s (NYSE:GSK) Nelkarmi (neladalkib) for locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). The milestone marks the second lung cancer approval this year for the European drug giant. Regulators cleared the kinase inhibitor for patients who previously received either one prior ALK tyrosine…
Source: Read the full story at Top Stories Feed